| Basal Cell Carcinoma |
1 |
1 |
| Lung Cancer |
0 |
0.3 |
| Skin Cancer |
0 |
0.93 |
| Biologic Therapy |
0 |
0.5 |
| Cancer |
0 |
0.9 |
| Non-Small Cell Lung Cancer |
0 |
0.71 |
| Toxicology |
0 |
0.65 |
| Squamous Cell Carcinoma |
0 |
0.57 |
| Cervical Cancer |
0 |
0.3 |
| Palliative Care |
0 |
0.3 |
| Advanced Cancer |
0 |
0.43 |
| Thyroid Disease |
0 |
0.3 |
| Europe |
0 |
0.41 |
| Small Cell Lung Cancer (SCLC) |
0 |
0.41 |
| Dermatitis |
0 |
0.3 |
| Id Reaction |
0 |
0.3 |
| Immunotherapy |
0 |
0.3 |
| Food and Drug Administration (FDA) |
0 |
0.2 |
| Grant |
0 |
0.2 |
| Tumor |
0 |
0.2 |
| Hypothyroidism |
0 |
0.18 |
| Hyperthyroidism |
0 |
0.12 |
| Inflammatory Bowel Disease |
0 |
0.12 |
| Blood |
0 |
0.1 |
| Clinical Research |
0 |
0.1 |
| Colitis |
0 |
0.1 |
| Hedgehog Pathway Inhibitor |
0 |
0.1 |
| Hepatitis |
0 |
0.1 |
| Hepatitis A |
0 |
0.1 |
| Intravenous |
0 |
0.1 |
| Lung |
0 |
0.1 |
| Pollex |
0 |
0.1 |
| Surgery |
0 |
0.1 |